Please use this identifier to cite or link to this item: http://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/10713
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPATIL, SRISHTIen_US
dc.contributor.authorAhmed, Armaanen_US
dc.contributor.authorViossat, Yannicken_US
dc.contributor.authorNoble, Roberten_US
dc.date.accessioned2026-02-26T04:58:58Z
dc.date.available2026-02-26T04:58:58Z
dc.date.issued2026-02en_US
dc.identifier.citationGenetics, 232(02).en_US
dc.identifier.issn1943-2631en_US
dc.identifier.urihttps://doi.org/10.1093/genetics/iyaf255en_US
dc.identifier.urihttp://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/10713
dc.description.abstractFirst-line cancer treatment frequently fails due to initially rare therapeutic resistance. An important clinical question is then how to schedule subsequent treatments to maximize the probability of tumor eradication. Here, we provide a theoretical solution to this problem by using mathematical analysis and extensive stochastic simulations within the framework of evolutionary rescue theory to determine how best to exploit the vulnerability of small tumors to stochastic extinction. Whereas standard clinical practice is to wait for evidence of relapse, we confirm a recent hypothesis that the optimal time to switch to a second treatment is when the tumor is close to its minimum size before relapse, when it is likely undetectable. This optimum can lie slightly before or slightly after the nadir, depending on tumor parameters. Given that this exact time point may be difficult to determine in practice, we study windows of high extinction probability that lie around the optimal switching point, showing that switching after the relapse has begun is typically better than switching too early. We further reveal how treatment efficacy and tumor demographic and evolutionary parameters influence the predicted clinical outcome, and we determine how best to schedule drugs of unequal efficacy. Our work establishes a foundation for further experimental and clinical investigation of this evolutionarily-informed multi-strike treatment strategy.en_US
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.subjectMathematical oncologyen_US
dc.subjectEvolutionary therapyen_US
dc.subjectEvolutionary rescueen_US
dc.subjectTherapeutic resistanceen_US
dc.subjectCancer treatmenten_US
dc.subjectExtinction therapyl|2026-FEB-WEEK3en_US
dc.subjectTOC-FEB-2026en_US
dc.subject2026en_US
dc.titlePreventing evolutionary rescue in cancer using two-strike therapyen_US
dc.typeArticleen_US
dc.contributor.departmentDept. of Mathematicsen_US
dc.identifier.sourcetitleGeneticsen_US
dc.publication.originofpublisherForeignen_US
Appears in Collections:JOURNAL ARTICLES

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.